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No biomarker panel is established for prediction of sinusoidal obstruction syndrome/veno-
occlusive disease (SOS/VOD), a major complication of allogeneic stem cell transplantation 
(alloSCT). We compared the potential of the Endothelial Activation and Stress Index 
(EASIX), based on lactate dehydrogenase, creatinine, and thrombocytes, with that of the 
SOS/VOD CIBMTR clinical risk score to predict SOS/VOD in two independent cohorts. In a 
third cohort, we studied the impact of endothelium-active prophylaxis with pravastatin and 
ursodeoxycholic acid (UDA) on SOS/VOD risk. The cumulative incidence of SOS/VOD within 
28 days after alloSCT in the training cohort (Berlin, 2013-2015, n=446) and in the validation 
cohort (Heidelberg, 2002-2009, n=380) was 9.6% and 8.4%, respectively. In both cohorts, 
EASIX assessed at the day of alloSCT (EASIX-d0) was significantly associated with 
SOS/VOD incidence (p<0.0001), overall survival (OS) and non-relapse mortality (NRM). In 
contrast, the CIBMTR score showed no statistically significant association with SOS/VOD 
incidence, and did not predict OS and NRM.  
In patients receiving pravastatin/UDA, the cumulative incidence of SOS/VOD was 
significantly lower at 1.7% (p<0.0001, Heidelberg, 2010-2015, n=359) than in the two cohorts 
not receiving pravastatin/UDA. The protective effect was most pronounced in patients with 
high EASIX-d0. The cumulative SOS/VOD incidence in the highest EASIX-d0 quartiles were 
18.1% and 16.8% in both cohorts without endothelial prophylaxis as compared to 2.2% in 
patients with pravastatin/UDA prophylaxis (p<0.0001). 
EASIX-d0 is the first validated biomarker for defining a subpopulation of alloSCT recipients at 
high risk for SOS/VOD. Statin/UDA endothelial prophylaxis could constitute a prophylactic 





Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), is a 
potentially fatal complication after allogeneic stem cell transplantation (alloSCT).1–3 Clinical 
management of SOS/VOD remains challenging, since there are no standardized predictive 
tools4 and diagnostic criteria are not uniform.2,4–6 The reported incidences of SOS/VOD after 
alloSCT range from 5.3% to 13.7% and vary depending on conditioning regimens, type of 
transplant, diagnostic criteria, patient characteristics, and other factors.7–9   
The pathophysiology of SOS/VOD is characterized by endothelial injury caused by the 
conditioning regimen as well as pre-transplant damage.1,2,10,11 The resulting post-sinusoidal 
portal hypertension leads to the clinical syndrome of SOS/VOD.2,5,6,11 In severe SOS/VOD, 
which is strongly associated with multi-organ failure, mortality remains high.2,8,11 Early 
detection or prediction of SOS/VOD could allow identification of patients benefiting from 
prophylactic measures,3 and preliminary data show that preemptive treatment with 
defibrotide might be effective,12 making tools for prediction of SOS/VOD highly desirable. 
Recently, a SOS/VOD clinical risk score (age, Karnofsky status, sirolimus use, hepatitis B/C 
status, conditioning regimen, disease type) has been published by the Center for 
International Blood and Marrow Transplant Research (CIBMTR).13 However, this score has 
not been validated outside of the CIBMTR database yet. In addition, it has been suggested 
that serum biomarkers, including microparticles and plasminogen activator inhibitor (PAI)-1, 
may be useful to predict SOS/VOD,14–18 but validation and clinical implementation of these 
non-routine biomarkers will be difficult due to the lack of standardization.  
Previously, we have developed a standard biomarker panel to assess endothelial dysfunction 
and activation, termed ‘Endothelial Activation and Stress Index (EASIX)’. EASIX is based on 
the simple formula “lactate dehydrogenase (LDH) (U/L) * creatinine (mg/dL) / thrombocytes 
(109 cells per L)” and thus calculated using three of the diagnostic parameters of thrombotic 
microangiopathy (TMA),19 which is another endothelial complication after alloSCT.20 EASIX 
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has also been shown to predict mortality of patients with acute graft-versus-host disease 
(GVHD).19  
With this background, the aim of the current study was to test the SOS/VOD predictive 





For this retrospective cohort analysis, a training cohort and a validation cohort comprising 
consecutive adult patients who had undergone alloSCT at two independent institutions were 
investigated. Patients from the training cohort received alloSCT at the Charité – Campus 
Virchow Klinikum, Berlin between 01/2013 – 12/2015. The validation cohort consisted of 
patients who were allografted at the University of Heidelberg between 09/2001 and 12/2009. 
Patients undergoing alloSCT in Heidelberg after 01/2010 received pravastatin and 
ursodeoxycholic acid (UDA) as prophylaxis of endothelial complications after alloSCT. To 
reduce confounding influences, the validation cohort was restricted to the time period before 
the introduction of pravastatin and UDA. The study was performed according to the 
declaration of Helsinki, with written informed consent obtained by all eligible patients. The 
study has been approved by the institutional review board of both institutions. 
Definitions  
SOS/VOD was defined according to the 2016 EBMT criteria for SOS/VOD diagnosis in 
adults.4 The disease score we applied for the patients classifies the disease stage of the 
main diseases acute leukemia, myelodysplastic syndrome, chronic myeloid leukemia and 
non-Hodgkin lymphoma/multiple myeloma. The disease stages are assigned according to 
the remission status at transplant or the phases of chronic myeloid leukemia. The stages 
include ‘early disease stage (0), ‘intermediate disease stage’ (1) and ‘late stage disease’ 
(2).21 
SOS/VOD CIBMTR risk score 
The SOS/VOD CIBMTR risk score has been established to assess the risk of developing 
SOS/VOD after alloSCT.13 It incorporates age, hepatitis B/C serology, Karnofsky 
performance status, use of sirolimus prophylaxis, disease, disease status at the time of 
transplant, and conditioning regimen. It was developed using the CIBMTR database.13 We 
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used the ‘VOD Risk Calculator’22 and recorded the probability of SOS/VOD development for 
each patient in the two independent cohorts when possible. 
EASIX Score 
The EASIX score was calculated using the formula: “LDH (U/L) * creatinine (mg/dL) / 
thrombocytes (109 cells per L)” as described previously, assessed at the day of alloSCT.19  
Statistical analyses 
The primary objective was prediction of SOS/VOD occurrence. Primary analysis was 
performed for the binary endpoint “cumulative incidence of SOS/VOD within 28 days after 
alloSCT” and the time-to-event endpoint “time to VOD (TTV)” which is defined as time from 
alloSCT to diagnosis of SOS/VOD. Secondary objectives were the prediction of OS and time 
to NRM measured from the day of alloSCT. TTV respectively NRM were analyzed using 
competing event models. The competing events are “non-SOS/VOD-mortality” defined as 
time from alloSCT to death without prior SOS/VOD respectively time to relapse defined as 
time from alloSCT to relapse of disease. Further details on statistical analyses are given in 





Patient characteristics  
The training cohort and the validation cohort consisted of 446 and 380 patients, respectively. 
The baseline characteristics are presented in Table 1. The patient cohorts were similar in 
regards to the characteristics age, sex, conditioning regimen and SOS/VOD incidence. 
However, there were significant differences in the categories donor type (more matched 
unrelated donors in the training cohort), underlying disease (most frequent disease: acute 
myeloid leukemia, 51% and 27% in the training and validation cohort, respectively), stem cell 
source (use of bone marrow more frequently in the validation cohort), and use of anti-T-cell 
globulin (ATG) (more commonly used in the training cohort). 
EASIX-d0 and SOS/VOD risk 
SOS/VOD was diagnosed in 43 patients (9.7%, median onset d +9) in the training cohort and 
in 32 patients (8.4%, median onset d +7) in the validation cohort. In the training cohort, 
median EASIX-d0 in patients who later on developed SOS/VOD was significantly higher as 
compared to patients who did not develop SOS/VOD (Figure 1A, p < 0.0001, 40.26; IQR 
14.72 – 80.38 vs. 16.06; IQR 6.00 – 36.54). These findings were confirmed in the validation 
cohort, where median EASIX-d0 in patients who subsequently developed SOS/VOD was 
also significantly higher as compared to patients who did not develop SOS/VOD (Figure 1B, 
p < 0.0001, 8.64; IQR 3.38 – 15.40 vs. 2.28; IQR 0.92 – 7.48). 
Increasing EASIX-d0 was significantly associated with SOS/VOD incidence in the training 
cohort in both univariable (OR per log2 increase 1.45, 95% CI 1.23-1.73, p < 0.0001) and 
multivariable analysis with the CIBMTR score as confounder (incorporating information on 6 
clinical variables) (OR per log2 increase 1.39, 95% CI 1.15-1.69, p = 0.0008) (Figure 2A). 
Similarly, EASIX-d0 was strongly associated with the incidence of SOS/VOD in the validation 
cohort (univariable analysis: OR per log2 increase 1.50, 95% CI 1.22-1.88, p = 0.0002; 




Based on this data, we have created the EASIX-d0 SOS/VOD calculator for free public use 
(http://biostatistics.dkfz.de/EASIX/). 
Association of EASIX-d0 with OS and NRM  
In the training cohort, EASIX-d0 was significantly associated with OS and NRM in univariable 
analysis (OS: HR per log2 increase 1.20, 95% CI 1.12-.1.29, p < 0.0001; NRM: cause-
specific hazard ratio (CSHR) per log2 increase 1.25, 95% CI 1.14-1.38, p < 0.0001) (Figure 
3A and 3C). Likewise, EASIX-d0 was significantly associated with OS and NRM in the 
validation cohort in univariable analysis (OS: HR per log2 increase 1.10, 95% CI 1.02-1.18, p 
= 0.0124.; NRM: CSHR per log2 increase 1.18, 95% CI 1.06-1.32, p = 0.0024) (Figure 3B 
and 3D). 
 
Association of the CIBMTR clinical risk score with SOS/VOD incidence, OS and NRM 
In the training cohort, a non-significant trend towards a higher median CIBMTR score was 
observed in patients who subsequently developed SOS/VOD as compared to patients who 
did not develop SOS/VOD (1.51; IQR 0.82 – 2.37 vs 1.01; IQR 0.76 – 1.80, p = 0.069). In the 
validation cohort, the median CIBMTR score in patients with SOS/VOD was significantly 
higher as compared to patients without SOS/VOD (1.92; IQR 1.44 – 3.09 vs 1.20; IQR 0.89 – 
2.15, p = 0.00053). On time-to-event analysis, however, the association of the CIBMTR score 
with SOS/VOD incidence was not statistically significant in the training cohort (Figure 4A, 
univariable analysis: OR per log2 increase 1.21, 95% CI 0.91-1.57, p = 0.152) nor in the 
validation cohort (Figure 4B, univariable analysis: OR per log2 increase 1.07, 95% CI 0.92-
1.20, p = 0.308).  
Brier score based on observed SOS/VOD incidence in the training cohort (null model) is 
0.0774 in the validation cohort. Inclusion of EASIX-d0 leads to a reduction of the quadratic 
prediction error (0.0735) of approximately 5%. In contrast to this, Brier score of the CIBMTR 
score model (0.0771) approximately coincides with Brier score of null model.  
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In both cohorts, the CIBMTR score was not predictive of OS or NRM (univariable analyses, 
training cohort, OS: HR per log2 increase 1.08, 95% CI 0.95-1.22, p = 0.2264; NRM: CSHR 
per log2 increase 1.15, 95% CI 1.00-1.33, p = 0.0565 / validation cohort, OS: HR per log2 
increase 1.03, 95% CI 0.97-1.03, p = 0.4126; NRM: CSHR per log2 increase 0.95, 95% CI 
0.84-1.08, p = 0.4648).  
Effect of pravastatin/UDA on SOS/VOD incidence  
Patients undergoing alloSCT in Heidelberg after 01/2010 received pravastatin and UDA as 
routine prophylaxis of endothelial complications after alloSCT. In this cohort of 359 
consecutive patients transplanted in Heidelberg between 01/2010 and 12/2015, the 
SOS/VOD incidence was significantly lower than in the training and validation cohorts treated 
without endothelial prophylaxis (Figure 5A, p < 0.0001; 1.7%, vs 9.6% and 8.4%). Next, we 
focused on the effect of pravastatin/UDA prophylaxis on SOS/VOD incidence, NRM and OS 
in a population at increased risk for SOS/VOD, defined by the highest EASIX-d0 quartile in 
each of the three cohorts. The patient cohort at increased risk that received pravastatin/UDA 
showed a significantly lower SOS/VOD incidence (Figure 5B), lower NRM (Figure 5C), and 
higher OS (Figure 5D) as compared to the high-risk patient populations in the training and 




In this retrospective cohort analysis, EASIX-d0 was found to be an independent predictor of 
SOS/VOD risk, OS and NRM in adult patients receiving alloSCT. EASIX-d0 constitutes the 
first validated biomarker for defining a subpopulation of alloSCT recipients at high risk for 
SOS/VOD. It consists of routine laboratory parameters enabling easy implementation in any 
transplant center. EASIX-d0 seems to be a readily available tool for stratifying patients into 
high- and low-risk populations, which could be useful to improve clinical management of 
SOS/VOD, and for identifying patient subsets for clinical trials on SOS/VOD prophylaxis. 
Outside of clinical studies, patients with high EASIX-d0 scores might benefit from closer 
monitoring of emerging clinical SOS/VOD signs and early interventions.  
EASIX-d0 has to be put in perspective with the CIBMTR SOS/VOD clinical risk score, which 
has been recently described as a predictive tool to identify patients at high risk of developing 
SOS/VOD.13 The CIBMTR score has been established using a large sample from the 
CIBMTR database and consists of select baseline parameters which are partly fixed (age, 
hepatitis B/C serology, Karnofsky performance score, diagnosis, disease status at transplant) 
and partly subject to intervention (use of sirolimus, conditioning regimen). It has been shown 
to be predictive for SOS/VOD but not for NRM and OS.13 In the present study, the CIBMTR 
score exhibited only a weak association with SOS/VOD incidence and no association with 
NRM or OS. One explanation for this discrepancy might be that the two European cohorts 
investigated in the current study were in some respects different from the CIBMTR cohort. 
First, in vivo T-cell depletion with ATG was administered in most patients in the two 
European cohorts, whereas the majority of the CIBMTR patients did not receive ATG for 
GVHD prophylaxis.13 Second, most patients in our two cohorts were conditioned with 
reduced intensity conditioning (RIC), whereas only a minority of patients from the CIBMTR 
database received a RIC regimen.13 Third, sirolimus was administered in 8% of the patients 
from the CIBMTR database, 13 whereas none of our patients received sirolimus 
prophylactically. This is relevant because sirolimus was a risk factor for SOS/VOD 
development in the CIBMTR analysis. In addition, registry data might be prone to 
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consistency deficits, while we had immediate access to the primary data ensuring high 
quality of data. Of note, the CIBMTR score has been primarily validated in a large population. 
We have validated the current EASIX-VOD score in smaller cohorts. Therefore, further 
validation is necessary. The EBMT is currently conducting a prospective non-interventional 
study on the value of the EASIX score for prediction of alloSCT-related endothelial 
complications. Furthermore, we expect that data from several retrospective cohorts in 
different centers will be available soon.  
 
Based on previous publications on the efficacy of UDA and statins in the protection of the 
endothelium,23,24 the Heidelberg alloSCT group decided to prophylactically administer 
pravastatin and UDA to alloSCT recipients transplanted after 01/2010. UDA is a synthetic 
bile acid that reduces the incidence of SOS/VOD, and is associated with less liver toxicity 
and better survival rates.3,25 Statins have not been extensively studied for the prevention of 
endothelial complications. However, its pleiotropic effects include, besides the inhibition of 
cholesterol synthesis, improvement of endothelial function, reduction of oxidative stress and 
inflammation, and decrease of thrombogenic properties.26,27 Statins may therefore be of 
beneficial effect in the prevention of endothelial complications. Accordingly, we observed a 
reduction of endothelial post-transplant complications, as previously shown in TMA20 and 
refractory GVHD28 upon implementation of statin/UDA endothelial prophylaxis.  
In the present study, the SOS/VOD incidence was markedly reduced after the introduction of 
pravastatin/UDA prophylaxis. These protective effects, both in terms of SOS/VOD risk 
reduction and lower NRM and overall mortality, were specifically pronounced in patients with 
high EASIX-d0 scores, as compared to high-risk patients that did not receive 
pravastatin/UDA. This suggests that patients at high risk for SOS/VOD may benefit most 
from prophylactic SOS/VOD strategies.   
Limitations of our study are its retrospective design and the validation in only one 
independent cohort of patients with similar patient characteristics, which are typical for adult 
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European alloSCT transplant centers. Therefore, the results cannot be extrapolated to 
pediatric alloSCT populations. Since EASIX-d0 is very easy to assess, any transplant center 
now has the opportunity to evaluate its potential in their respective patient population and we 
hope that more data on different patient populations, including pediatric patients or 
haploidentical transplantation, will be available soon. To facilitate this process, we have 
created the EASIX-d0 SOS/VOD calculator for free public use 
(http://biostatistics.dkfz.de/EASIX/). 
In conclusion, EASIX-d0 seems to be an easy-to-use biomarker for identifying patient 
populations at high risk for SOS/VOD, and thus could be a promising tool both for clinical 
trials and tailored monitoring strategies. Statin/UDA endothelial prophylaxis could be an 
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(n = 380) 
Heidelberg  with 
statins/UDA cohort 
(n = 359) 
P Berlin vs 
Heidelberg no 
statins/UDA 
P Berlin vs 
Heidelberg with 
statins/UDA 




Date of alloSCT 01/2013 – 12/2015 09/2001 – 01/2010 01/2010 – 12/2015 
      
Age at transplant in years - median 
(range) 54 (18-75) 50 (17-70) 56 (19-75) 
      
Recipient sex (n, %)   
  
  0,668 0,942 0,764 
- Female 172 (39%) 153 (40%) 140 (39%) 
      
- Male 274 (61%) 227 (60%) 219 (61%) 
      
Donor sex   
  
  0,877 0,437 0,584 
- Female 124 (28%) 121 (32%) 122 (34%) 
      
- Male 274 (61%) 259 (68%) 237 (66%) 
      
- NA 48 (11%)   
        
Donor   
  
  
<0,001 0,034 <0,001 
- Matched related donor 88 (20%) 141 (37%) 94 (26%) 
      
- Matched unrelated donor 263 (59%) 140 (37%) 196 (55%) 
      
- Mismatched related donor 6 (1%) 14 (4%) 11 (3%) 
      
- Mismatched unrelated donor 89 (20%) 85(22%) 58 (16%) 
      
Disease   
  
  
<0,001 <0,001 <0,001 
- AML 229 (51%) 101 (27%) 126 (35%) 
      
- MDS/MPN 82 (18%) 53 (14%) 69 (19%) 
      
- ALL 35 (8%) 39 (10%) 20 (6%) 
      
- lymphoma 41 (9%) 96 (25%) 100 (28%)       
- MM 39 (9%) 75 (20%) 36 (10%)       
- Other 20 (4%) 16 (4%) 8 (2%)       
Disease score   
  
  
0,012 <0,001 <0,001 
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- 0 142 (32%) 131 (34%) 122 (34%)       
- 1 47 (11%) 65 (17%) 122 (34%)       
- 2 248 (56%) 184 (48%) 115 (32%)       
- NA 9 (2%)   
        
Stem-cell source   
  
  
<0,001 <0,001 0,566 
- Peripheral blood 443 (99%) 351 (92%) 336 (94%)       
- Bone marrow 2 (1%) 29 (8%) 23 (6%)       
- NA 1 (0%)   
        
Conditioning   
  
  0,999 0,055 0,069 
- RIC 341 (76%) 291 (77%) 294 (82%)       
- MAC 105 (24%) 89 (23%) 64 (18%)       
Use of ATG   
  
  
<0,001 <0,001 <0,001 
- Yes 399 (89%) 193 (51%) 259 (72%)       
- No 47 (11%) 187 (49%) 100 (28%)       
SOS/VOD development (EBMT criteria)   
  
  0,472 <0,001 <0,001 
- SOS/VOD 43 (10%) 32 (8%) 6 (2%)       
- No SOS/VOD 401 (90%) 348 (92%) 353 (98%)       
Onset of SOS/VOD (median, range) d+9 (d+3 to d+30) d+8 (d0 to d+24) d+10 (d+1 to d+17)       
Median CIBMTR score (range, IQR)   
  
        
SOS/VOD 
n = 32, rest of data NA: 
1.51 (0.56 – 4.48; 0.82 
– 2.37) 
n = 29, rest of data 
NA: 1.9 (0.3 – 8.7; 
1.4 – 3.1) 
n = 5, rest of data NA: 
1.7 (0.7 – 3.7; 1.0 – 
2.7) 
      
No SOS/VOD 
n = 338, rest of data 
NA: 1.01 (0.32 – 9.72; 
0.76 – 1.80) 
n = 333, rest of data 
NA: 1.2 (0.4 – 20.6; 
0.9 - 2.1) 
n = 347, rest of data 
NA: 1.0 (0.3 – 9.1; 
0.8– 1.7) 
      
Median EASIX-d0 (range, IQR)   
  
        
SOS/VOD 
n = 41, rest of data NA: 
40.26: (5.23 – 865.06; 
14.72 – 80.38) 
n = 32, rest of data 
NA: 8.6 (0.2 – 41.0; 
3.4– 15.4) 
n = 6 rest of data NA: 
7.4 (4.0 – 17.1; 5.8-
14.8) 
      
No SOS/VOD 
n = 376, rest of data 
NA: 16.06 (0.38 – 575; 
6.00 – 36.54) 
n = 348, rest of data 
NA: 2.3 (0.2 – 99.2; 
0.9 – 7.5) 
n = 353, rest of data 
NA: 7.5 (0.2 – 195.8; 
2.1 – 14.9) 




UDA = ursodeoxycholic acid, alloSCT = allogeneic stem cell transplantation, NA = not available, AML = acute myeloid leukemia, MDS = 5 
myelodysplastic syndrome, ALL = acute lymphocytic leukemia, CLL = chronic lymphocytic leukemia, MPN = myeloproliferative neoplasms, CML = 
chronic myeloid leukemia, MM = multiple myeloma, RIC = reduced intensity conditioning, MAC =  myeloablative conditioning, ATG = anti-





Figure 1: EASIX-d0 in patients without SOS/VOD vs EASIX-d0 in patients with 
SOS/VOD. Box plot of EASIX-d0 in patients without SOS/VOD (No VOD) vs EASIX-d0 in 
patients with SOS/VOD in (A) the training and (B) the validation cohort. 
Figure 2: Time to SOS/VOD depending on EASIX-d0 quartiles. (A) Training and (B) 
validation cohort. 
Figure 3: Univariable effect of EASIX-d0 on overall survival and non-relapse mortality. 
Univariable effect of EASIX-d0 on overall survival in (A) the training cohort and (B) the 
validation cohort. Univariable association of EASIX-d0 with non-relapse mortality in (C) the 
training cohort and (D) the validation cohort. 
Figure 4: Time to SOS/VOD depending on CIBMTR score quartiles. (A) Training and (B) 
validation cohort. 
Figure 5: Effects of pravastatin/UDA prophylaxis (blue) compared to the training 
cohort (green) and the validation cohort (red). 
(A) Time to SOS/VOD in the three cohorts.  
(B) Time to SOS/VOD in patients with the highest EASIX-d0 quartiles in the three 
cohorts. 
(C) Time to NRM in patients with the highest EASIX d0 quartile in the three cohorts. 










Patient, laboratory and clinical data were accessed retrospectively using the clinical data 
management software SAP and COPRA. 
 
Definitions 
EBMT criteria for SOS/VOD diagnosis in adults: These criteria differentiate between classical 
SOS/VOD, which occurs in the first 21 days after stem cell transplantation, and late-onset 
SOS/VOD, which occurs beyond 21 days after stem cell transplantation. Classical SOS/VOD 
diagnosis requires bilirubin levels to be ≥ 2 mg/dL and two of the following criteria to be 
present: painful hepatomegaly, weight gain > 5%, and ascites. Late onset SOS/VOD can be 
diagnosed if the classical criteria are met, SOS/VOD is histologically proven, or if 
hemodynamical or/and ultrasound evidence of SOS/VOD are present and at least two of the 
four EBMT criteria are met. 
 
Statistical analyses 
The primary objective was prediction of SOS/VOD occurrence. Primary analysis was 
performed for the binary endpoint “cumulative incidence of SOS/VOD within 28 days after 
alloSCT” and the time-to-event endpoint “time to VOD (TTV)” which is defined as time from 
alloSCT to diagnosis of SOS/VOD. Secondary objectives were the prediction of OS and time 
to NRM measured from the day of alloSCT. TTV respectively NRM were analyzed using 
competing event models. The competing events are “non-SOS/VOD-mortality” defined as 
time from alloSCT to death without prior SOS/VOD respectively time to relapse defined as 
time from alloSCT to relapse of disease.  
Categorical variables are presented as numbers and percentages. Continuous variables are 
presented as medians and ranges or interquartile ranges (IQR). For the primary statistical 
analysis of EASIX-d0, the log2 transformed index, log2(EASIX) = log2(LDH) + 
log2(creatinine) – log2 (thrombocytes) was used.  
Median follow-up time was estimated using the reverse Kaplan-Meier method. The analyses 
of the binary endpoint SOS/VOD within 100 days after alloSCT were performed using logistic 
regression models. We report estimated odds ratios (OR) and corresponding confidence 
intervals. The OR is the ratio of the estimated odds for a SOS/VOD event given a defined 
risk factor and the odds for a SOS/VOD event in the absence of this risk factor. Survival and 
incidence curves are based on the Kaplan-Meier estimator respectively Aalen-Johanson 
estimator for competing risk scenarios. For univariable and multivariable analyses of OS and 
NRM, (cause-specific) Cox proportional hazards models were used. Hazard ratios (HR) were 
calculated to demonstrate the prognostic effect of biomarkers. To check whether EASIX-d0 
improves individual risk prediction in the presence of the well-established CIBMTR score, we 
trained a multivariable model with log2(EASIX) and the individual risk prediction from the 
CIBMTR calculator as covariates.  
Validation of univariate EASIX-d0 and CIBMTR SOS/VOD model (Berlin) was performed in 
an external validation cohort (Heidelberg, no pravastatin/UDA). Discriminative ability was 
assessed using ROC-curves and AUC. Additionally, the Brier score was included which is a 
function measuring the accuracy of predictions. In contrast to the c-index, the Brier score 
checks for both, discrimination as well as calibration of the model. If the Brier score of a 
statistical model (including EASIX) is lower than the Brier score of the null model (without 
EASIX), a better prediction (of SOS/VOD) is indicated. 
Pravastatin and UDA were routinely applied in the Heidelberg cohort starting in 01/2010, 
whereas the training cohort did not regularly receive pravastatin and UDA as prophylaxis. To 
assess differences in the prognostic effect of EASIX-d0 between subgroups of patients with 
pravastatin/UDA prophylaxis or no pravastatin/UDA prophylaxis, separate subset Cox 
regression models for the Heidelberg cohort were performed (Heidelberg no pravastatin/UDA 
vs Heidelberg with pravastatin/UDA). Estimates based on the univariate logistic training 
cohort model can be obtained via an online calculator which is available on 
http://biostatistics.dkfz.de/EASIX/. The tool provides an estimate of the probability for 
SOS/VOD within 28 days after alloSCT and a corresponding confidence interval given a 
certain EASIX-d0 value. 
